NCT00104910 - Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2013

Conditions

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell CarcinomaStage IB Cervical CancerStage IIA Cervical CancerStage IIB Cervical CancerStage III Cervical CancerStage IVA Cervical Cancer

Interventions

RADIATION

Internal Radiation Therapy

RADIATION

3-Dimensional Conformal Radiation Therapy

BIOLOGICAL

Cetuximab

Given IV

DRUG

Cisplatin

Given IV

Trial Locations (15)

21287

Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore

30912

Georgia Regents University Medical Center, Augusta

43214

Riverside Methodist Hospital, Columbus

44060

Lake University Ireland Cancer Center, Mentor

44109

MetroHealth Medical Center, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

52242

University of Iowa Hospitals and Clinics, Iowa City

60637

University of Chicago Comprehensive Cancer Center, Chicago

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75235

Parkland Memorial Hospital, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

77030

M D Anderson Cancer Center, Houston

08103

Cooper Hospital University Medical Center, Camden

02905

Women and Infants Hospital, Providence

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK